|
Name |
Isoleucyl-Proline
|
| Molecular Formula | C11H20N2O3 | |
| IUPAC Name* |
(2S)-1-[(2S,3S)-2-amino-3-methylpentanoyl]pyrrolidine-2-carboxylic acid
|
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N
|
|
| InChI |
InChI=1S/C11H20N2O3/c1-3-7(2)9(12)10(14)13-6-4-5-8(13)11(15)16/h7-9H,3-6,12H2,1-2H3,(H,15,16)/t7-,8-,9-/m0/s1
|
|
| InChIKey |
BBIXOODYWPFNDT-CIUDSAMLSA-N
|
|
| Synonyms |
Isoleucyl-Proline; 37462-92-3; H-Ile-Pro-OH; ile-pro; L-isoleucyl-L-proline; Isoleucylproline; L-Proline, L-isoleucyl-; (2S)-1-[(2S,3S)-2-amino-3-methylpentanoyl]pyrrolidine-2-carboxylic acid; CHEMBL1807684; CHEBI:74076; L-Ile-L-Pro; SCHEMBL231857; DTXSID70332168; ZINC1591038; BDBM50348850; MFCD02259535; AKOS010419475; Q27144389
|
|
| CAS | 37462-92-3 | |
| PubChem CID | 444876 | |
| ChEMBL ID | CHEMBL1807684 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 228.29 | ALogp: | -1.8 |
| HBD: | 2 | HBA: | 4 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 83.6 | Aromatic Rings: | 1 |
| Heavy Atoms: | 16 | QED Weighted: | 0.746 |
| Caco-2 Permeability: | -5.889 | MDCK Permeability: | 0.00140286 |
| Pgp-inhibitor: | 0.01 | Pgp-substrate: | 0.007 |
| Human Intestinal Absorption (HIA): | 0.3 | 20% Bioavailability (F20%): | 0.004 |
| 30% Bioavailability (F30%): | 0.004 |
| Blood-Brain-Barrier Penetration (BBB): | 0.949 | Plasma Protein Binding (PPB): | 10.70% |
| Volume Distribution (VD): | 0.373 | Fu: | 80.98% |
| CYP1A2-inhibitor: | 0.011 | CYP1A2-substrate: | 0.067 |
| CYP2C19-inhibitor: | 0.056 | CYP2C19-substrate: | 0.185 |
| CYP2C9-inhibitor: | 0.016 | CYP2C9-substrate: | 0.308 |
| CYP2D6-inhibitor: | 0.058 | CYP2D6-substrate: | 0.191 |
| CYP3A4-inhibitor: | 0.013 | CYP3A4-substrate: | 0.067 |
| Clearance (CL): | 8.273 | Half-life (T1/2): | 0.778 |
| hERG Blockers: | 0.015 | Human Hepatotoxicity (H-HT): | 0.596 |
| Drug-inuced Liver Injury (DILI): | 0.241 | AMES Toxicity: | 0.003 |
| Rat Oral Acute Toxicity: | 0.034 | Maximum Recommended Daily Dose: | 0.03 |
| Skin Sensitization: | 0.124 | Carcinogencity: | 0.02 |
| Eye Corrosion: | 0.004 | Eye Irritation: | 0.032 |
| Respiratory Toxicity: | 0.201 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000749 | ![]() |
0.680 | D0I0EG | ![]() |
0.612 | ||
| ENC000810 | ![]() |
0.591 | D00SEB | ![]() |
0.393 | ||
| ENC000918 | ![]() |
0.484 | D0N5HJ | ![]() |
0.388 | ||
| ENC001906 | ![]() |
0.462 | D07HGR | ![]() |
0.323 | ||
| ENC000141 | ![]() |
0.422 | D0X5SJ | ![]() |
0.322 | ||
| ENC000001 | ![]() |
0.306 | D03KYG | ![]() |
0.299 | ||
| ENC002115 | ![]() |
0.304 | D0E1XL | ![]() |
0.276 | ||
| ENC001303 | ![]() |
0.281 | D08BTB | ![]() |
0.264 | ||
| ENC004972 | ![]() |
0.277 | D01STB | ![]() |
0.260 | ||
| ENC005975 | ![]() |
0.277 | D0N4EC | ![]() |
0.258 | ||